CytoMed Therapeutics Limited (GDTC)
NASDAQ:GDTC
Want to see GDTC full AI Analyst Report?
Total Valuation
CytoMed Therapeutics Limited has a market cap or net worth of $11.71M. The enterprise value is $10.10M.
Market Cap$11.71M
Enterprise Value$10.10M
Share Statistics
CytoMed Therapeutics Limited has 11,832,835 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,832,835
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
CytoMed Therapeutics Limited’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -47.92%.
Return on Equity (ROE)-0.47
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-47.92%
Return on Capital Employed (ROCE)-0.48
Revenue Per Employee5.77K
Profits Per Employee-92.94K
Employee Count43
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of CytoMed Therapeutics Limited is ―. CytoMed Therapeutics Limited’s PEG ratio is -0.08.
PE Ratio―
PS Ratio62.86
PB Ratio2.38
Price to Fair Value2.38
Price to FCF-3.55
Price to Operating Cash Flow-3.47
PEG Ratio-0.08
Income Statement
In the last 12 months, CytoMed Therapeutics Limited had revenue of 248.27K and earned -3.05M in profits. Earnings per share was -0.26.
Revenue248.27K
Gross Profit-689.55K
Operating Income-3.52M
Pretax Income-3.06M
Net Income-3.05M
EBITDA-3.34M
Earnings Per Share (EPS)-0.26
Cash Flow
In the last 12 months, operating cash flow was -2.82M and capital expenditures -497.95K, giving a free cash flow of -3.32M billion.
Operating Cash Flow-2.82M
Free Cash Flow-3.32M
Free Cash Flow per Share-0.28
Dividends & Yields
CytoMed Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.21
52-Week Price Change-57.03%
50-Day Moving Average1.04
200-Day Moving Average1.62
Relative Strength Index (RSI)47.82
Average Volume (3m)166.79K
Important Dates
CytoMed Therapeutics Limited upcoming earnings date is May 4, 2026, During Market Hours (Confirmed).
Last Earnings DateNov 14, 2025
Next Earnings DateMay 4, 2026
Ex-Dividend Date―
Financial Position
CytoMed Therapeutics Limited as a current ratio of 5.17, with Debt / Equity ratio of 7.37%
Current Ratio5.17
Quick Ratio5.17
Debt to Market Cap0.03
Net Debt to EBITDA0.48
Interest Coverage Ratio-219.71
Taxes
In the past 12 months, CytoMed Therapeutics Limited has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
CytoMed Therapeutics Limited EV to EBITDA ratio is -4.19, with an EV/FCF ratio of -3.18.
EV to Sales56.37
EV to EBITDA-4.19
EV to Free Cash Flow-3.18
EV to Operating Cash Flow-3.78
Balance Sheet
CytoMed Therapeutics Limited has $2.10M in cash and marketable securities with $482.56K in debt, giving a net cash position of $1.61M billion.
Cash & Marketable Securities$2.10M
Total Debt$482.56K
Net Cash$1.61M
Net Cash Per Share$0.14
Tangible Book Value Per Share$0.58
Margins
Gross margin is -38.33%, with operating margin of -1415.96%, and net profit margin of -1227.07%.
Gross Margin-38.33%
Operating Margin-1415.96%
Pretax Margin-1231.97%
Net Profit Margin-1227.07%
EBITDA Margin-1346.04%
EBIT Margin-1415.96%
Analyst Forecast
The average price target for CytoMed Therapeutics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast373.88%
EPS Growth Forecast-59.79%